BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barrea L, Muscogiuri G, Modica R, Altieri B, Pugliese G, Minotta R, Faggiano A, Colao A, Savastano S. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:649496. [PMID: 33815296 DOI: 10.3389/fendo.2021.649496] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Abe K, Kitago M, Iwasaki E, Yagi H, Abe Y, Hasegawa Y, Hori S, Tanaka M, Nakano Y, Kitagawa Y. Reconsideration of operative indications in pancreatic neuroendocrine neoplasms. World J Surg Onc 2022;20:366. [DOI: 10.1186/s12957-022-02834-5] [Reference Citation Analysis]
2 Scherübl H. Metabolisches Syndrom und gastrointestinale Krebsvorsorge. Z Gastroenterol 2022. [DOI: 10.1055/a-1959-3829] [Reference Citation Analysis]
3 Liang W, Xu X, Liu Y, Cui J, Gao Y, Wang C, Zhuang Z, Zhang K, Xi H, Cai A, Wei B, Chen L. Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis. World J Surg Onc 2022;20:356. [DOI: 10.1186/s12957-022-02822-9] [Reference Citation Analysis]
4 Modica R, La Salvia A, Liccardi A, Cannavale G, Minotta R, Benevento E, Faggiano A, Colao A. Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target. Metabolites 2022;12:1057. [DOI: 10.3390/metabo12111057] [Reference Citation Analysis]
5 Muscogiuri G, Barrea L, Cantone MC, Guarnotta V, Mazzilli R, Verde L, Vetrani C, Colao A, Faggiano A; NIKE. Neuroendocrine Tumors: A Comprehensive Review on Nutritional Approaches. Cancers (Basel) 2022;14:4402. [PMID: 36139562 DOI: 10.3390/cancers14184402] [Reference Citation Analysis]
6 Gaudenzi G, Vitale G. Indici cardio-metabolici e sindrome metabolica come predittori prognostici nei tumori neuroendocrini gastroenteropancreatici. L'Endocrinologo 2022;23:437-438. [DOI: 10.1007/s40619-022-01142-0] [Reference Citation Analysis]
7 Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 2022;:1-15. [PMID: 35822906 DOI: 10.1080/17446651.2022.2099840] [Reference Citation Analysis]
8 Ranallo N, Iamurri AP, Foca F, Liverani C, De Vita A, Mercatali L, Calabrese C, Spadazzi C, Fabbri C, Cavaliere D, Galassi R, Severi S, Sansovini M, Tartaglia A, Pieri F, Crudi L, Bianchini D, Barone D, Martinelli G, Frassineti GL, Ibrahim T, Calabrò L, Berardi R, Bongiovanni A. Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. Cancers 2022;14:3231. [DOI: 10.3390/cancers14133231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Abdel-Rahman O, Ghosh S, Morrish D. Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms. J Endocrinol Invest 2022. [PMID: 35606667 DOI: 10.1007/s40618-022-01805-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Muscogiuri G, Zanata I, Barrea L, Cozzolino A, Filice E, Messina E, Colao A, Faggiano A; on behalf of NIKE Group. A practical nutritional guideline to manage neuroendocrine neoplasms through chronotype and sleep. Crit Rev Food Sci Nutr 2022;:1-18. [PMID: 35285728 DOI: 10.1080/10408398.2022.2047882] [Reference Citation Analysis]
11 Natalicchio A, Faggiano A, Zatelli MC, Argentiero A, D'Oronzo S, Marrano N, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi R, Ferrari P, Gori S, Morviducci L, Russo A, Tuveri E, Montagnani M, Gallo M, Silvestris N, Giorgino F. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2021;:103572. [PMID: 34954047 DOI: 10.1016/j.critrevonc.2021.103572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ismaiel A, Jaaouani A, Leucuta DC, Popa SL, Dumitrascu DL. The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis. Biomedicines 2021;9:1890. [PMID: 34944706 DOI: 10.3390/biomedicines9121890] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Barrea L, Muscogiuri G, Pugliese G, de Alteriis G, Colao A, Savastano S. Metabolically Healthy Obesity (MHO) vs. Metabolically Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with Endocrine-Metabolic Profile, Adherence to the Mediterranean Diet, and Body Composition. Nutrients 2021;13:3925. [PMID: 34836180 DOI: 10.3390/nu13113925] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]